Leronlimab’s ability to downregulate intracellul
Post# of 149916
Quote:
Leronlimab’s ability to downregulate intracellular Ca²⁺ could indeed have interesting implications for transglutaminase-2 (TG2) activity, but calling it a cure for HIV would be a big leap. Here’s why:
HIV Persistence & Reservoirs – A true cure for HIV would require eliminating or functionally silencing latent viral reservoirs. Leronlimab primarily blocks the CCR5 co-receptor, preventing new infections but not necessarily eradicating existing reservoirs.
ChatGpt must not keep up with Dr. Sacha's work.
Quote:
3. Could This Prevent HIV Transmission?
A contraceptive for HIV (or a preventative method) would need to stop viral transmission at mucosal surfaces (vaginal, rectal, etc.).
Leronlimab primarily works inside immune cells, meaning it’s not directly a topical or systemic barrier against HIV entry like PrEP (e.g., Truvada, Descovy).
Leronlimab doesn't work inside immune cells, it blocks the cell surface expressed CCR5 receptor. ChatGpt doesn't think blocking HIV from entering the very cells it needs to reproduce is a barrier? Truvada and Descovy don't block entry of HIV, they stop the replication of the virus after it's already entered the cell.
Quote:
Leronlimab only works against CCR5-tropic HIV (~60-70% of new infections).
I don't know where they're getting 60% to 70% of new infections. Initial transmission of HIV via CXCR4 is fairly rare.